Clinical Trial

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-11
notable Enrollment reduced: 30 -> 17 participants 2026-07-11
Trial Details
NCT Number NCT05458674
Lead Sponsor Criterium, Inc.
Conditions Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Enrollment 17 participants
Start Date 2024-01-30
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-10